| Liquidia Corporation | 2.45M | US$195M | 17.7% |
| Eton Pharmaceuticals, Inc. | 2.86M | US$104M | 9.4% |
| Harrow, Inc. | 2.4M | US$102M | 9.2% |
| Disc Medicine, Inc. | 855K | US$62.5M | 5.7% |
| Apogee Therapeutics, Inc. | 390K | US$51.8M | 4.7% |
| Meiragtx Holdings Plc | 3.55M | US$48M | 4.3% |
| Rezolute, Inc. | 6.3M | US$32.8M | 3.0% |
| Tg Therapeutics, Inc. | 535K | US$29.4M | 2.7% |
| Immix Biopharma, Inc. | 2.35M | US$24.2M | 2.2% |
| Crescent Biopharma, Inc. | 1.32M | US$23.7M | 2.2% |
| Stoke Therapeutics, Inc. | 700K | US$22.9M | 2.1% |
| Alpha Cognition Inc. | 2.9M | US$20.9M | 1.9% |
| Edgewise Therapeutics, Inc. | 500K | US$20.3M | 1.8% |
| Revolution Medicines, Inc. | 100K | US$18.7M | 1.7% |
| Monte Rosa Therapeutics, Inc. | 745K | US$18M | 1.6% |
| Alumis Inc. | 550K | US$15.5M | 1.4% |
| Codexis, Inc. | 6.79M | US$15.3M | 1.4% |
| Replimune Group, Inc. | 1.38M | US$15.3M | 1.4% |
| Xoma Royalty Corporation | 338K | US$14.4M | 1.3% |
| Mbx Biosciences, Inc. | 260K | US$14.4M | 1.3% |
| Rhythm Pharmaceuticals, Inc. | 123K | US$13.6M | 1.2% |
| Editas Medicine, Inc. | 3.86M | US$12.5M | 1.1% |
| Protagonist Therapeutics, Inc. | 100K | US$12.3M | 1.1% |
| Cabaletta Bio, Inc. | 3.86M | US$12M | 1.1% |
| Q32 Bio Inc. | 931K | US$11.9M | 1.1% |
| Annexon, Inc. | 1.71M | US$9.79M | 0.89% |
| Verastem, Inc. | 1.8M | US$6.88M | 0.62% |
| Zentalis Pharmaceuticals, Inc. | 1.41M | US$6.85M | 0.62% |
| Relmada Therapeutics, Inc. | 935K | US$6.47M | 0.59% |
| Ocular Therapeutix, Inc. | 600K | US$5.89M | 0.53% |
| Trevi Therapeutics, Inc. | 310K | US$5.78M | 0.52% |
| Bridgebio Oncology Therapeutics, Inc. | 700K | US$5.33M | 0.48% |
| Lyell Immunopharma, Inc. | 344K | US$4.83M | 0.44% |
| Opus Genetics, Inc. | 1.13M | US$4.62M | 0.42% |
| 4d Molecular Therapeutics, Inc. | 334K | US$4.45M | 0.40% |
| Intellia Therapeutics, Inc. | 250K | US$4.23M | 0.38% |
| Voyager Therapeutics, Inc. | 1.19M | US$4.15M | 0.38% |
| Biodesix, Inc. | 180K | US$4.06M | 0.37% |
| Rocket Pharmaceuticals, Inc. | 1M | US$3.42M | 0.31% |
| Jade Biosciences, Inc. | 145K | US$3.22M | 0.29% |
| Sanuwave Health, Inc. | 306K | US$3.06M | 0.28% |
| Fortress Biotech, Inc. | 890K | US$2.72M | 0.25% |
| Journey Medical Corporation | 350K | US$2.48M | 0.22% |
| Phathom Pharmaceuticals, Inc. | 186K | US$2.01M | 0.18% |
| Inhibrx Biosciences, Inc. | 20,291 | US$1.92M | 0.17% |
| Enanta Pharmaceuticals, Inc. | 125K | US$1.82M | 0.17% |
| Hemab Therapeutics Holdings, Inc. | 47,652 | US$1.75M | 0.16% |
| First Tracks Biotherapeutics, Inc. | 65,000 | US$1.31M | 0.12% |
| Cg Oncology, Inc. | 17,789 | US$1.26M | 0.11% |
| Biohaven Ltd. | 77,915 | US$1.16M | 0.10% |
| Atea Pharmaceuticals, Inc. | 235K | US$1.09M | 0.10% |
| Pasithea Therapeutics Corp. | 2.05M | US$1.06M | 0.10% |
| Palatin Technologies, Inc. | 20,500 | US$221K | 0.02% |
| Adagio Medical Holdings, Inc | 18,444 | US$13,353 | <0.01% |
| Assertio Holdings, Inc. | 0 | US$0 | 0.00% |
| Lb Pharmaceuticals Inc | 0 | US$0 | 0.00% |
| Nextcure, Inc. | 0 | US$0 | 0.00% |
| Perspective Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Protalix Biotherapeutics, Inc. (de) | 0 | US$0 | 0.00% |
| Rigel Pharmaceuticals, Inc. | 0 | US$0 | 0.00% |
| Sutro Biopharma, Inc. | 0 | US$0 | 0.00% |
| Tectonic Therapeutic, Inc. | 0 | US$0 | 0.00% |